Trial · NCT01786512
Adverse event totals33
The totals the trial posted for each group.
1 to 20 of 33
Download this page as JSON| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Dose-escalation Cohort 1: Placebo | ||
| Total, all-cause mortality | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1 | ||
| Total, all-cause mortality | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2 | ||
| Total, all-cause mortality | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2 | ||
| Total, all-cause mortality | Dose-escalation Cohort 2: Placebo | ||
| Total, all-cause mortality | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1 | ||
| Total, all-cause mortality | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2 | ||
| Total, all-cause mortality | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2 | ||
| Total, all-cause mortality | Expansion Phase: Placebo | ||
| Total, all-cause mortality | Expansion Phase: Omecamtiv Mecarbil 25 mg | ||
| Total, all-cause mortality | Expansion Phase: OM PK-based Titration | ||
| Total, other adverse events | Dose-escalation Cohort 1: Placebo | 4 | 11 |
| Total, other adverse events | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1 | 2 | 10 |
| Total, other adverse events | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2 | 5 | 14 |
| Total, other adverse events | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2 | 6 | 13 |
| Total, other adverse events | Dose-escalation Cohort 2: Placebo | 1 | 10 |
| Total, other adverse events | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1 | 8 | 11 |
| Total, other adverse events | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2 | 3 | 11 |
| Total, other adverse events | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2 | 4 | 14 |
| Total, other adverse events | Expansion Phase: Placebo | 48 | 149 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01786512/event-totals